Skip to main content
PMC home page
European Radiology Experimental logoLink to European Radiology Experimental
. 2017 Nov 2;1:21. doi: 10.1186/s41747-017-0024-3

Manganese-enhanced MRI for the detection of metastatic potential in colorectal cancer

liang Wen 1,✉, Xinan Shi 2, Liping He 2, Yi Lu 1, Dan Han 1
PMCID: PMC5909354  PMID: 29708197

Abstract

Background

To study manganese superoxide dismutase (MnSOD) expression, manganese-enhanced magnetic resonance imaging (MEMRI) appearance and its relation to metastatic potential in colorectal cancer (CRC).

Methods

CRC cells SW620, HCT116, LoVo, SW480, DLD-1, HCT15, Caco-2 and their normal counterpart CCD841 CoN were chosen, based on differential aggressiveness, to undergo Western blot analysis for assessment of MnSOD expression, reported as proportion of readings to internal reference (glyceraldehyde-3-phosphate-dehydrogenase). Based on the results of the invasion assay, HCT15, DLD-1, LoVo and SW620 cells and corresponding xenografts underwent MEMRI. The differences of average T1-value shortening were compared.

Results

MnSOD expression in SW620, HCT116, LoVo, SW480, DLD-1, HCT15, Caco-2 and CCD841 CoN cells (0.255 ± 0.018 (mean ± standard deviation), 0.289 ± 0.028, 0.438 ± 0.028, 0.337 ± 0.025, 0.777 ± 0.031, 1.045 ± 0.038, 0.163 ± 0.035 and 0.185 ± 0.038, respectively) was not correlated with Invasion Index (22.6 ± 0.7, 17.0 ± 0.6, 20.9 ± 0.6, 9.7 ± 0.4, 7.5 ± 0.3, 8.3 ± 0.2, 12.6 ± 0.5 and 0) (r = − 0.204, p = 0.627). In highly aggressive cells (SW620, LoVo), T1 shortening (289.33 ± 0.57, 268.45 ± 6.87 ms, respectively) was greater than that in lower counterparts (148.68 ± 3.99 ms in DLD-1, 128.60 ± 1.96 in HCT15) (p < 0.001). Both 5- and 10-mm group SW620 and/or LoVo tumours showed greater T1 shortening (≥600 ms) than DLD-1 and HCT15 (≤350 ms) (p < 0.001, p = 0.005, p = 0.010).

Conclusions

MEMRI has the potential to noninvasively distinguish different metastatic potential CRCs. However, the MnSOD expression is not correlated to malignant potential in CRC cells.

Keywords: Colorectal cancer, Contrast-enhanced magnetic resonance imaging (MRI), Manganese, Metastatic potential, Manganese superoxide dismutase

Keypoints

  • MEMRI detects metastatic potential in CRC

  • MnSOD is upregulated in most CRC cells

  • MnSOD expression is not correlated with metastatic potential

Background

Colorectal cancer (CRC) is the third most common cancer and the fourth most common cancer cause of death globally. The stage at diagnosis, frequently with presence of liver metastases, is the most important prognostic factor. Presently, CRC diagnosis and staging mainly rely on colonoscopy and computed tomography (CT) examination [1]. Colonoscopy is able to detect small, primary lesions while CT enables the assessment of lymph node and liver involvement. However, both examinations are not able to suggest the metastatic potential of the primary lesion which is directly associated with prognosis and therapy selection. Magnetic resonance imaging (MRI) has proved to be more accurate in detecting hepatic metastatic lesions of less than 10 mm compared with CT [2]. Associated with the administration of hepatobiliary-specific contrast agents, MRI has been shown to allow an improved sensitivity [3, 4]. Notably, up to 20% of CRC patients have developed remote metastasis at first diagnosis and between 25 and 50% of postoperative patients develop liver metastasis within 3 years after surgery [5–7]. Thus, though there is no current role for MRI-derived biomarkers in predicting metastatic potential of the primary CRC, this perspective deserves to be explored.

Previous researches have documented that manganese superoxide dismutase (MnSOD) expression or activity is upregulated in CRC in comparison with adjacent normal mucosa; moreover, the expression or activity level of this enzyme was not only associated with the depth of invasion, venous plexus involvement and clinical stage [8–12] but also could be an independent prognostic factor for poor 5-year survival of CRC patients [13]. A similar correlation was also reported for breast, lung and bladder neoplasms [14]. However, more recent studies found no correlation between MnSOD expression or activity and clinical stage in CRC [15, 16].

Based on the fact that Mn is bound to SOD as a cofactor for enzymatic activity [17] and that divalent manganese ion (Mn2+) has strong paramagnetic effect to alter the longitudinal relaxation of water [18], we tried to employ MnCl2 solution as a contrast agent to perform manganese-enhanced MRI (MEMRI) on human CRC cell lines and subcutaneous xenograft tumours. Our aim was to test the MEMRI capability of noninvasively detecting aggressiveness of CRC and, furthermore, to link the MRI appearance of MnSOD expression in CRC cells.

Methods

Cell lines

Human CRC cell lines with high metastatic potential (SW620, HCT116, LoVo) and low metastatic potential (SW480, DLD-1, HCT15, Caco-2) as well as normal colon cells CCD841 CoN were purchased from an American-type culture collection (Manassas, VA, USA). The malignant potential of cancer cells has been documented by previous studies [19–24]. These cell lines were cultured in Roswell Park Memorial Institute 1640 (Sigma-Aldrich, St Louis, MO, USA) medium containing 10% foetal bovine serum (Invitrogen, Rockville, MD, USA) at 37 °C in 5% CO2 and 95% humidified air.

Invasion assay

To verify the cell aggressiveness documented by previous studies [19–24] and justify the cell selection for MEMRI invasion, assay was performed by using transwell inserts coated with matrigel basement membrane matrix (BD Biosciences, San Jose, CA, USA) and incubated in humidified 5% CO2 at 37 °C for 72 h. The cells on the top membrane and the bottom surface were observed and recorded under the microscope (Carl Zeiss, Canton, China). Five fields were randomly selected and counted as mean value of cell number in each membrane. The percentage of cells that have migrated through the membrane was calculated and was recorded as the Invasion Index. The experiments were repeated twice and the results were averaged.

Western blot

Anti-SOD2 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were purchased from Cell Signaling (Danvers, MA, USA). Cells were lysed with radio-immunoprecipitation assay buffer containing 1 mM phenylmethanesulphonyl fluoride and protease inhibitor cocktail for 30 min at 4 °C. After centrifugation for 15 min at 13,000 rpm, the supernatants were recovered and the protein concentration was measured by bicinchoninic acid Protein Assay Kit (Thermo Fisher Scientific, Waltham, MA, USA). Equal amounts of cell lysates were resolved in 5 × sodium dodecylsulphate and transferred onto nitrocellulose membranes (Sigma-Aldrich, St Louis, MO, USA). After blocking, the membranes were incubated sequentially with the appropriate diluted primary and secondary antibodies. Proteins were detected by the enhanced chemiluminescence detection system (Amersham, Piscataway, NJ, USA). To ensure equal loading of the samples, the membranes were re-probed with a GAPDH antibody (Cell Signaling Technologies, Danvers, MA, USA). The MnSOD expression level was reported as the proportion of readings to internal reference GAPDH.

In vitro MRI

Based on results of the invasion study, two cells with the highest Invasion Index and the two least aggressive cells were selected to test their Mn uptake at MRI, using normal cell CCD841 CoN as control. MnCl2 was dissolved in the culture medium at 0.1 mM for cell lines in the exponential growth phase. After incubation for 60 min, the cells underwent centrifugation at 1000 g for 10 min at 37 °C, 5% CO2. The supernatant was removed and fresh medium was added to rinse the cell pellets. After that, the cells were centrifuged and the cell pellets were rinsed again under the same condition for final centrifugation. Corresponding cell lines without administration of MnCl2 were also centrifuged in the same way. Then, the cell pellets at a depth of about 10 mm in a Corning tube (1.5 ml) were imaged.

The imaging acquisition was performed using a 1.5-T MRI scanner (Intera, Philips Medical Systems, Best, The Netherlands) equipped with a gradient system with a 30-mT/m maximum amplitude, 0.2-ms minimal rise time and 150-T/m/s maximum slew rate. An eight-element head radiofrequency coil was used. The temperature in the scanner bore was approximately 25 °C. Both T1-weighted imaging (T1WI) and T1-mapping were acquired along axial planes. Firstly, two-dimensional (2D) spin-echo T1WI (2D SE T1WI) was performed with the following technical parameters: time of repetition (TR) 597.22 ms; time of echo (TE) 12.40 ms; field of view (FOV) 60 mm; slice thickness 1 mm; inter-slice interval 1 mm; number of excitations (NEX) 20; matrix 144 × 144. Then, a 2D inversion-recovery turbo spin-echo (2D IR TSE) was performed for T1-mapping, with the following technical parameters: TR 3000 ms; TE 18.5 ms; time of interpulse (TI) 50, 100, 250, 500, 750, 1000, 1250, 1500, 2000 and 2500 ms; slice thickness 1 mm; inter-slice interval 1 mm; FOV 60 mm; NEX 20; matrix 144 × 144. Data calculation and analyses were conducted by a home-made program developed in MatLab (version 7.0; MathWorks, Natick, MA, USA). Both T1 relaxation times with and without Mn administration were calculated on a pixel-by-pixel basis. Two independent measurements were made and the average value was recorded. A region of interest (ROI) of about 17 mm2 was manually encircled at the cell-pellet section (Fig. 1). The average T1-value shortening was calculated as follows: T1 value of cells with 0 mM minus T1 value of cells with 0.1 mM. Two independent experiments were carried out.

Fig. 1.

Fig. 1

Open in a new tab

Axial T1-weighted imaging of colorectal cancer (CRC) cells after MnCl2 incubation. Regions of interest were manually placed to include the entire cell pellet area

Subcutaneous xenografted model on nude mice

This study was approved by the local Animal Care Ethics Committee. Female BALB/c nude mice were kept under specific pathogen-free conditions and cared for in accordance with the guidelines of the Laboratory Animal Ethics Committee. The average weight of the mice was 15 g per mouse. Keeping conditions light/dark the cycle shifted every 12 h. The temperature was 27 °C and the humidity was 50%. The cages, food and water used for the mice were sterilised. For the implanted tumours’ growth assay, two high-metastatic-potential and two low-metastatic-potential cells in 1 × 106/0.2 ml phosphate buffered saline were injected subcutaneously into the right flank of each mouse. Tumour size was measured daily.

In vivo MRI

At least three nude mice were randomly chosen to undergo MRI when the tumours’ greatest diameter reached 5 and 10 mm, respectively. A 3.0-T scanner (Achieva, Philips Medical Systems, Best, The Netherlands) equipped with a Quasar Dual Gradient system with 80-mT/m maximum amplitude, 0.16-ms minimal rise time and 200-T/m/s maximum slew rate was used. A small-bore, phased-array, radiofrequency coil was used. MnCl2 × 4H2O (Sigma-Aldrich, St Louis, MO, USA) was dissolved in distilled water to make a 100-mM solution, further diluted with isotonic saline to 50 mM. The mice were anaesthetised with 1.5% isoflurane in the prone position with head down. The temperature of the mice was maintained by an air-warming system at approximately 37 °C. The tumour was placed at the centre of the coil and the MRI acquisitions were performed along the axial plane. Firstly, 2D TSE T1WI was performed with the following parameters: TR 626.17 ms; TE 23 ms; slice thickness 2 mm; inter-slice interval 1 mm; FOV 40 mm; matrix 320 × 320. Secondly, T1- mapping was performed using the variable flip angle method through a three-dimensional, fat-saturated, T1WI turbo field-echo with the following technical parameters: TR 6.9 ms, TE 3.7 ms; flip angle 2°, 10° and 20°; NEX 16; slice thickness 2 mm; inter-slice interval 1 mm; FOV 40 mm; matrix = 256 × 256 [25, 26]. Then, 0.3 μmol/g of 50 mM MnCl2 solution was injected intraperitoneally. An intravenous injection of Mn2+ was not performed to avoid acute Mn toxicity, taking into consideration the rapid Mn release into the circulation. Manganese-enhanced T1WI and T1-mapping with same parameters were performed again 24 h later. Then, the animals were sacrificed and the excised xenograft tumours were fixed in 10% neutral formalin for routine hematoxylin-eosin staining and CD34 immunohistochemical study. Microvessel density counting was also carried out. The data processing was similar to that previously mentioned. The entire tumour margin on every section was outlined and the average T1 relaxation time was recorded. Measurement for each tumour was repeated three times and average results were recorded.

Statistical analysis

SPSS version 13.0 (SPSS inc, Chicago, IL, USA) was used to perform the analysis. Because the main purpose of the invasion assay was to verify cell aggressiveness and facilitate cell selection for MEMRI, the statistical analysis was not performed for the results of the invasion assay. The data underwent the Shapiro-Wilk test to analyse their normality. Differences in MnSOD expression level, in vitro Mn uptake of cells and T1-value shortening of xenografts were compared by using one-way analysis of variance, respectively. The Student-Newman-Keuls q test was then performed for pairwise comparison. Correlation between MnSOD expression and aggressiveness was analysed by Pearson linear correlation analysis. The results with a p value lower than 0.050 were reported as statistically significant.

Results

Aggressiveness of cells

CRC cells SW620, HCT116, LoVo, SW480, DLD-1, HCT15 and Caco-2 showed various metastatic potentials. SW620 and LoVo had the highest Invasion Index whereas DLD-1 and HCT15 had the lowest one. Normal mucosal cells CCD841 CoN showed an Invasion Index of 0 (Fig. 2).

Fig. 2.

Fig. 2

Open in a new tab

Invasion assay results of cells. SW620, LoVo and DLD-1, HCT15 have shown the highest and lowest Invasion Index, respectively

MnSOD expression in cell lines

All seven CRC cell lines and normal cells expressed certain levels of MnSOD. Cancer cell lines showed higher levels of expression than normal cell lines except for Caco-2 (0.163 ± 0.035), its expression being slightly lower than that of normal cell lines (0.185 ± 0.038), without statistical significance. The cells with the highest expression level of MnSOD were HCT15 and DLD-1 (1.045 ± 0.038, 0.777 ± 0.031), both having a low metastatic potential. Cells with relatively high MnSOD expression encompassed both high- and low-metastatic-potential cells, LoVo, SW620, HCT116 and SW480 (0.438 ± 0.028, 0.255 ± 0.018, 0.289 ± 0.028 and 0.337 ± 0.025, respectively). Compared with their normal counterpart, DLD-1 and HCT15 cells demonstrated a marked increase of MnSOD expression (p = 0.001, p < 0.001) while the MnSOD expression of SW480 and LoVo cells was increased (p = 0.031, p = 0.012). Although SW620 and HCT116 showed a higher MnSOD expression than normal cells, no statistical significance was found (p = 0.067) (Fig. 3). Regression analyses did not find a significant correlation between the expression level of MnSOD and cell aggressiveness (r = − 0.204, p = 0.627) (Table 1).

Fig. 3.

Fig. 3

Open in a new tab

Human colorectal cell cancer and normal cell lines’ manganese superoxide dismutase (MnSOD) expression. a Western blot analysis of MnSOD protein with GAPDH as control. b Quantitative assessment of MnSOD expression level. Low-metastatic-potential cells DLD-1 and HCT15 have significantly increased expression, high-metastatic-potential cell LoVo and low-metastatic-potential cell SW480 show increased expression. High-metastatic-potential cell SW620 has increased expression but no statistical significance was found. *p = 0.031, p = 0.012; **p = 0.001; ***p < 0.001

Table 1.

Manganese superoxide dismutase (MnSOD) expression level and Invasion Index of cells

CCD841 CoN DLD-1 HCT15 SW480 Caco-2 HCT116 LoVo SW620
MnSOD expression level 0.185 ± 0.038 0.777 ± 0.031 1.045 ± 0.038 0.337 ± 0.025 0.163 ± 0.035 0.289 ± 0.028 0.438 ± 0.028 0.255 ± 0.018
Invasion Index (%) 0 7.5 ± 0.3 8.3 ± 0.2 9.7 ± 0.4 12.0 ± 0.5 17.0 ± 0.6 20.0 ± 0.6 22.0 ± 0.7
Open in a new tab

MnSOD data are mean and standard deviation of the proportion of readings to internal reference (glyceraldehyde-3-phosphate-dehydrogenase)

In vitro MEMRI of Mn uptake in cell lines

All five cell lines incubated in the medium with 0.1-mM MnCl2 exhibited a certain degree of Mn uptake shown on T1WI as increased signal intensity compared with cells without the administration of MnCl2 (Fig. 4). Further T1-mapping analysis demonstrated that the average T1-value shortening in SW620 and LoVo cells (289.33 ± 0.57 and 268.45 ± 6.87 ms) was significantly higher than DLD-1 and HCT15 (148.68 ± 3.99 and 128.60 ± 1.96 ms) (p < 0.001 for both). All cancer cells have shown significantly greater T1-value shortening compared with normal cell (p < 0.001) (Table 2).

Fig. 4.

Fig. 4

Open in a new tab

In vitro manganese-enhanced magnetic resonance imaging of cell lines. T1-weighted imaging of cell pellets incubated with and without 0.1-mM MnCl2. Cancer cells enhance more markedly than do normal cells and high-metastatic-potential cells SW620 and LoVo enhance the most

Table 2.

Comparison of T1-value shortening in cells at manganese-enhanced magnetic resonance imaging

Cell lines ‾Mean ± standard deviation F P
SW620 289.33 ± 0.57 2039.259 <0.001
LoVo 268.45 ± 6.87
HCT15 128.60 ± 1.96
DLD-1 148.68 ± 3.99
CCD841 CoN 65.12 ± 0.12
Open in a new tab

High-metastatic-potential cells SW620 and LoVo show significantly greater T1 shortening than low-metastatic-potential cells DLD-1 and HCT15 (p < 0.001, analysis of variance). Measurement is based on two independent experiments

Subcutaneous tumour MRI and histopathology

The numbers of successfully developed xenografts is shown in Table 3. Twenty-nine tumours displayed iso- or slightly higher signal intensity relative to muscle on 2D TSE T1WI. On T1 mapping, the difference in average tumour T1-value shortening in the 5-mm group compared by one-way analysis of variance showed that both SW620 (n = 5; 730.56 ± 33.48 ms) and LoVo xenografts (n = 3; 637.57 ± 47.62 ms) were significantly greater than DLD-1 (n = 5; 265.28 ± 19.59 ms) and HCT15 (n = 4; 262.60 ± 46.48 ms) (p < 0.001 for both). One-way analysis of variance in the 10-mm group tumours has shown that T1 shortening in LoVo xenografts (n = 3; 620.33 ± 88.60 ms) was significantly greater than in DLD-1 (n = 6 ; 346.82 ± 108.04 ms) and HCT15 (n = 3; 341.97 ± 112.12 ms) (p = 0.005, p = 0.010, respectively). However, no statistical difference was found between LoVo and SW620, as well as DLD-1 and HCT15 tumours in neither the 5- nor the 10-mm group (p = 0.107) (Table 4, Fig. 5). The routine hematoxylin-eosin staining verified that all 29 xenografts were moderate- to low-differentiated adenocarcinoma. Under the light microscope the packed neoplastic cells were patchily distributed with sparse interstitium and discrete coagulative necrosis was found. Sparse microvessels were shown on CD34 staining, the minimum and maximum microvessel density counts were 11.4 and 20, respectively, with an average count of 15.6 per × 200 field (Fig. 6).

Table 3.

Xenografts successfully developed in 5- and 10-mm size groups

Tumour number
Tumour 5 mm 10 mm
LoVo 3 3
SW620 5 0
DLD-1 5 6
HCT15 4 3
Open in a new tab

Table 4.

T1-value shortening of xenografts in 5- and 10-mm size groups

Greatest diameter of tumours (mm)
Tumours 5 mm 10 mm
SW620 730.56 ± 33.48c,d —
LoVo 637.57 ± 47.62c,d 620.33 ± 88.60c,d
DLD-1 265.28 ± 19.5a,b 346.82 ± 108.04b
HCT15 262.60 ± 46.48a,b 341.97 ± 112.12b
Open in a new tab

Data are expressed as mean ± standard deviation

Symbols indicate that the difference between SW620 (a), LoVo (b), DLD-1 (c) and HCT15 (d) is statistically significant

Fig. 5.

Fig. 5

Open in a new tab

T1-weighted imaging of pre- and post-Mn administration in 5- and 10-mm group xenografts. Arrows in the images from a to n point to subcutaneous tumour. Images a, c, e, g, i, k, m and b, d, f, h, j, l and n represent pre- and post-Mn administration, respectively. Images a, b and k, l are low-metastatic-potential DLD-1 tumours. Images c and d are of a high-metastatic-potential SW620 tumour. Images e, f and i, j are low-metastatic-potential HCT15 tumours. Images g, h and m, n are high-metastatic-potential LoVo tumours. SW620 and LoVo tumours display greater enhancement than DLD-1 and HCT15 tumours

Fig. 6.

Fig. 6

Open in a new tab

a and b are a histological photomicrographs (hematoxylin and eosin × 40) and CD34 immunohistochemical staining (×200) of a DLD-1 tumour, respectively. In a, packed tumour cells with little interstitium (black arrow) and discrete necrosis (white arrow) are shown. In b, black arrows point to sparse microvessels. c and d are a histological photomicrograph (haematoxylin and eosin × 100) and CD34 immunohistochemical staining (×200) of a SW620 tumour, respectively. In c, relatively little interstitium (white arrow) is noted in packed tumour cells. In d, white arrows indicate sparse microvessels

Discussion

The current approaches for diagnosing and staging CRC are not able to noninvasively define tumour malignant potential that is directly correlated with therapy selection and prognosis. The controversial results regarding the relation between MnSOD expression and tumour malignant potential in CRC reported in clinical researches, and some results concerning MEMRI of neoplasms from recent studies [27–38], inspired us to explore the application of MEMRI in noninvasive evaluation of CRC metastatic potential. In addition, the attempt to correlate MEMRI appearance with MnSOD expression in CRC cells was made.

Our invasion assay has verified the differential metastatic potential of seven CRC cells, which was consistent with the results reported in previous studies. These researches documented that SW620 and LoVo cells were derived from metastatic lymph nodes of colorectal cancer, the tumourigenicity, growth kinetics and metastatic potential of these cells were proved to be more aggressive than in SW480, DLD-1, HCT15 and Caco-2 that were derived from primary tumours [19–24]. Our study confirmed that SW620, LoVo and DLD-1, HCT15 have shown the highest and lowest Invasion Index, respectively.

As one of the most important antioxidant enzymes, MnSOD protein has been considered downregulated in malignant neoplasms in the earliest studies, though subsequent researchers have found increased MnSOD expression in malignant mesothelioma and some neoplasms arising from thyroid, kidney and central nervous system cells as well as in CRC in most clinical studies [14]. This was verified in our in vitro experiment. However, the relation between MnSOD expression and malignant potential is more complicated. Some clinical studies have shown that MnSOD expression is positively correlated with CRC malignant potential [8–12]. However, our in vitro study found that the cells with the highest MnSOD expression had low metastatic potential, whereas cells with a relatively low expression encompassed both high and low metastatic potentials. This indicates that the expression of MnSOD in CRC cells was not correlated to malignant potential. Because the expression of MnSOD is a response to oxidative stress [39, 40], the microenvironmental redox status of tumours influences its expression. The different redox status in human body and cell culture environments might contribute to the discrepancy between the present study and previous clinical researches.

In this study, both MEMRI studies in cells and xenografts have shown significant difference in T1 shortening between CRCs with different metastatic potential: highly aggressive cells/tumours showed two to three times greater T1 shortening than less aggressive ones, with high statistical significance. Similar findings were reported by Nofiele et al. in human breast cancer cells [36]. The author observed that the Mn induced a longitudinal relaxation rate (R1) in the most aggressive cells significantly higher (two times) than that in less aggressive ones. Based on these results, it could be postulated that MEMRI might be used to distinguish aggressiveness in cancers.

Mn2 + is a well-known intracellular contrast agent for MRI. It is taken up and accumulated by cells and shortens the T1 relaxation time of adjacent water thanks to its strong paramagnetic effect. Compared with extracellular agents (such as Gd-based contrast agents), its enhancement effect is more dependent on cell density than on tumour vascularity. At a biochemical level, Mn is involved in mitochondrial function, and the greater the mitochondrial density, the higher the level of Mn uptake. Hence, it could be speculated that tumours with higher cell density and/or mitochondria would enhance more markedly on MEMRI. This was reflected in our study by the fact that the xenografts that were significantly enhanced with Mn administration have invariably shown histological features of packed tumour cells though only sparse microvessels were found.

At molecular level, several factors involving Mn2+ uptake in cells have been reported such as voltage-gated Ca2+-channel activity, anti-N-methyl-D-aspartate, astroglia and microglia activity/cellularity, and metal transporters [41]. However, the mechanism involved in Mn2+ uptake in tumour cells is not fully understood. In a study of human breast cancer the overexpression of calcium-sensing receptor (CaSR) in tumour was suggested to be involved in better Mn-enhancement [29]. However, another study attempting to link CaSR expression to Mn-enhancement in human breast cancer cells did not find this correlation [36]. Nevertheless, the authors found that the most aggressive cells that showed the lowest level of CaSR expression enhanced the most markedly whereas the less aggressive cells with higher levels of CaSR expression enhanced only minimally; furthermore, the higher the concentration of MnCl2 administration, the greater the enhancement of both cells. This indicates that, although CaSR plays a role in Mn uptake in tumour cells via its ion-channel regulation, the T1 shortening effect of Mn2+ on MRI could not be explained solely by ion-channel activity.

Obviously, differential biological behavior of tumours and Mn2+ concentration are also involved in Mn-enhancement. The fact that our study employed identical Mn2+ concentration for different cells and tumours either in in-vitro or in in-vivo studies, and that different aggressive malignancies still showed differential Mn-enhancement, further underscores the important role of neoplastic cell biological properties in MEMRI appearance. Actually, two researches have documented the relation between the biological properties of tumour cells and the Mn-enhancement effect in MRI. Braun et al. [30] found that some tumour cells with a higher proliferation rate demonstrated more Mn uptake and greater T1 shortening. Saito et al. [41] detected early cell alteration that was identified by cell-cycle and proliferation changes after irradiation exposure both in vitro and in vivo by using MEMRI. Therefore, it seems reasonable to attribute the greater Mn-enhancement in more aggressive CRC to a higher cell proliferation rate.

Apart from Mn uptake, the subcellular location of intracellular Mn2+ may also contribute to the enhancement effect. Free Mn2+ in cytosol has greater access to water to induce more T1 shortening compared with mitochondrial Mn2+. Because of the more severe functional impairment of mitochondria in more malignant tumour cells, the Mn2+ entering the mitochondria might be less than that in less aggressive tumour cells, resulting in more Mn2+ accumulating freely in cytosol, thus causing greater T1 shortening. Finally, the contribution from Mn2+ in the extracellular compartment should probably also not be overlooked [42].

In addition, studies in malignant mesothelioma [34, 43] favoured the hypothesis that greater Mn-enhancement is related to higher MnSOD expression in tumours. However, in our study the relatively low MnSOD expression cells has clearly shown greater Mn-enhancement than in cells with higher expression. Given that MnSOD is located in the mitochondria and needs binding Mn2+ to activate it, it was speculated that cells with a lower MnSOD expression have a lower intracellular Mn2+ concentration, which leaves more space for further Mn2+ uptake. As a consequence, its T1 shortening was greater than in cells with high MnSOD expression. The contraindicated observations indicate that this relation is not consistent in different cancer types.

In summary, the tumour-enhancement effect of Mn appears to be influenced mainly by the following factors: tumour cellularity, ion-channel regulation, cell-cycle and proliferation rate, tumour aggressiveness, subcellular location of Mn2+ as well as MRI technical issues such as agent concentration. However, to what extent each single factor contributes to MEMRI appearance under certain imaging condition still needs studies to clarify.

Manganese toxicity is the main obstacle to translate this MEMRI study into clinical application. Finding the appropriate dosage that generates a sufficient enhancement effect with minimum adverse effects would be the prerequisite to translate animal study into clinical use. However, even the most widely used gadolinium-based MRI contrast agents are not free of adverse effects. Recently, they have been found to induce nephrogenic systemic fibrosis in the presence of renal failure [44] and the problem of gadolinium deposition in various organs is of increasing concern [45, 46]. On the other hand, an orally administered Mn agent, such as CMC-001, has shown promising results in terms of reducing toxic effects and improving the detection of liver metastases in both in-vitro studies and clinical trials [3, 47]. Newly developed Mn-based magnetic nanoparticles also have the potential to reduce toxicity and increase the specificity to target tumours [47]. Given that a significant portion of CRC patients developed remote metastasis, either at first diagnosis or after surgery [5–7], MEMRI approaches evaluating tumour metastatic potential prior to the occurrence of remote metastatic disease could provide valuable information for prognosis and therapy planning. This technique might be also applied to other neoplasms other than CRC.

In conclusion, MEMRI showed the potential to noninvasively distinguish high- from low-metastatic-potential CRC by revealing a greater T1 shortening in the former. However, the MnSOD expression in CRC cells did not correlate with malignant potential.

Acknowledgements

We thank the Institutional Animal Care Committee for granting permission for this study. We also thank the guarantor, Dan Han, for advice on the study design. The coauthor. Dr. Liping He, has contributed with expertise in statics.

Funding

Applied basic research project-union foundation of science and technique department of Yunnan technique department of Yunnan Province and Kunming Medical University (2017FE467(-048)).

Abbreviations

2D SE

Two-dimensional spin-echo

2D

Two-dimensional

CaSR

Calcium-sensing receptor

CRC

Colorectal cancer

CT

Computed tomography

FOV

Field of view

GAPDH

Glyceraldehyde-3-phosphate dehydrogenase

MEMRI

Manganese-enhanced magnetic resonance imaging

MnSOD

Manganese superoxide dismutase

NEX

Number of excitations

T1WI

T1-weighted imaging

TE

Time of echo

TR

Time of repetition

Authors’ contributions

LW contributed to the study design, data collection, manuscript preparation, drafting and revision. XS, LH, YL and DH were involved in the study design. LH contributed to the statistical analysis. All authors read and approved the final manuscript.

Ethics approval and consent to participate

This experimental study was performed according to regulations issued by our local Institutional Review Board.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Contributor Information

liang Wen, Email: wlleon007@126.com.

Xinan Shi, Email: xilancixiang@163.com.

Liping He, Email: lipinghe2@126.com.

Yi Lu, Email: aspirell@163.com.

Dan Han , Email: wlleon007@163.com.

References

  • 1.Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet. 2014;383:1490–1502. doi: 10.1016/S0140-6736(13)61649-9. [DOI] [PubMed] [Google Scholar]
  • 2.Kaur H, Choi H, You YN, et al. MR imaging for preoperative evaluation of primary rectal cancer: practical considerations. Radiographics. 2012;32:389–409. doi: 10.1148/rg.322115122. [DOI] [PubMed] [Google Scholar]
  • 3.Brismar TB, Kartalis N, Kylander C, Albiin N. MRI of colorectal cancer liver metastases: comparison of orally administered manganese with intravenously administered gadobenate dimeglumine. Eur Radiol. 2012;22:633–641. doi: 10.1007/s00330-011-2288-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Giuga M, De Gaetano AM, Guerra A, et al. An update on clinical applications of hepatospecific contrast media in magnetic resonance imaging of liver parenchyma. Eur Rev Med Pharmacol Sci. 2016;20:2515–2525. [PubMed] [Google Scholar]
  • 5.Sietses C, Meijerink MR, Meijer S, van den Tol MP. The impact of intraoperative ultrasonography on the surgical treatment of patients with colorectal liver metastases. Surg Endosc. 2010;24:1917–1922. doi: 10.1007/s00464-009-0874-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Ellsmere J, Kane R, Grinbaum R, Edwards M, Schneider B, Jones D. Intraoperative ultrasonography during planned liver resections: why are we still performing it? Surg Endosc. 2007;21:1280–1283. doi: 10.1007/s00464-006-9192-6. [DOI] [PubMed] [Google Scholar]
  • 7.Lupinacci R, Penna C, Nordlinger B (2007) Hepatectomy for resectable colorectal cancer metastases—indicators of prognosis, definition of resectability, techniques and outcomes. Surg Oncol Clin N Am 16:493–506, vii-viii [DOI] [PubMed]
  • 8.Gopcevic KR, Rovcanin BR, Tatic SB, Krivokapic ZV, Gajic MM, Dragutinovic VV. Activity of superoxide dismutase, catalase, glutathione peroxidase, and glutathione reductase in different stages of colorectal carcinoma. Dig Dis Sci. 2013;58:2646–2652. doi: 10.1007/s10620-013-2681-2. [DOI] [PubMed] [Google Scholar]
  • 9.Janssen AM, Bosman CB, Kruidenier L, et al. Superoxide dismutases in the human colorectal cancer sequence. J Cancer Res Clin Oncol. 1999;125:327–335. doi: 10.1007/s004320050282. [DOI] [PubMed] [Google Scholar]
  • 10.Nozoe T, Honda M, Inutsuka S, Yasuda M, Korenaga D. Significance of immunohistochemical expression of manganese superoxide dismutase as a marker of malignant potential in colorectal carcinoma. Oncol Rep. 2003;10:39–43. [PubMed] [Google Scholar]
  • 11.Satomi A, Murakami S, Hashimoto T, Ishida K, Matsuki M, Sonoda M. Significance of superoxide dismutase (SOD) in human colorectal cancer tissue: correlation with malignant intensity. J Gastroenterol. 1995;30:177–182. doi: 10.1007/BF02348662. [DOI] [PubMed] [Google Scholar]
  • 12.Toh Y, Kuninaka S, Oshiro T, et al. Overexpression of manganese superoxide dismutase mRNA may correlate with aggressiveness in gastric and colorectal adenocarcinomas. Int J Oncol. 2000;17:107–112. doi: 10.3892/ijo.17.1.107. [DOI] [PubMed] [Google Scholar]
  • 13.Janssen AM, Bosman CB, Sier CF, et al. Superoxide dismutases in relation to the overall survival of colorectal cancer patients. Br J Cancer. 1998;78:1051–1057. doi: 10.1038/bjc.1998.626. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Hempel N, Carrico PM, Melendez JA. Manganese superoxide dismutase (Sod2) and redox-control of signaling events that drive metastasis. Anticancer Agents Med Chem. 2011;11:191–201. doi: 10.2174/187152011795255911. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Nalkiran I, Turan S, Arikan S, et al. Determination of gene expression and serum levels of MnSOD and GPX1 in colorectal cancer. Anticancer Res. 2015;35:255–259. [PubMed] [Google Scholar]
  • 16.Skrzycki M, Majewska M, Podsiad M, Czeczot H. Expression and activity of superoxide dismutase isoenzymes in colorectal cancer. Acta Biochim Pol. 2009;56:663–670. [PubMed] [Google Scholar]
  • 17.Culotta VC, Yang M, O’Halloran TV. Activation of superoxide dismutases: putting the metal to the pedal. Biochim Biophys Acta. 2006;1763:747–758. doi: 10.1016/j.bbamcr.2006.05.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Massaad CA, Pautler RG. Manganese-enhanced magnetic resonance imaging (MEMRI) Methods Mol Biol. 2011;711:145–174. doi: 10.1007/978-1-61737-992-5_7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Brattain MG, Levine AE, Chakrabarty S, Yeoman LC, Willson JK, Long B. Heterogeneity of human colon carcinoma. Cancer Metastasis Rev. 1984;3:177–191. doi: 10.1007/BF00048384. [DOI] [PubMed] [Google Scholar]
  • 20.Chowdhury S, Ongchin M, Sharratt E, et al. Intra-tumoral heterogeneity in metastatic potential and survival signaling between iso-clonal HCT116 and HCT116b human colon carcinoma cell lines. PLoS One. 2013;8:e60299. doi: 10.1371/journal.pone.0060299. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Guo Q, Tang W, Inagaki Y, et al. Subcellular localization of KL-6 mucin in colorectal carcinoma cell lines: association with metastatic potential and cell morphology. Oncol Rep. 2007;17:1057–1060. [PubMed] [Google Scholar]
  • 22.Kramer R, Weber TK, Morse B, et al. Constitutive expression of multidrug resistance in human colorectal tumours and cell lines. Br J Cancer. 1993;67:959–968. doi: 10.1038/bjc.1993.177. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Li X, Ding Y, Cai J, Zhang S. The expression of sialyl Lewis-X antigen in LoVo, HT29 cell lines of colorectal cancer and its correlation with metastatic potential. Zhonghua Bing Li Xue Za Zhi. 2000;29:119–122. [PubMed] [Google Scholar]
  • 24.Trainer DL, Kline T, McCabe FL, et al. Biological characterization and oncogene expression in human colorectal carcinoma cell lines. Int J Cancer. 1988;41:287–296. doi: 10.1002/ijc.2910410221. [DOI] [PubMed] [Google Scholar]
  • 25.Cheng HL, Wright GA. Rapid high-resolution T(1) mapping by variable flip angles: accurate and precise measurements in the presence of radiofrequency field inhomogeneity. Magn Reson Med. 2006;55:566–574. doi: 10.1002/mrm.20791. [DOI] [PubMed] [Google Scholar]
  • 26.Cheng HL, Stikov N, Ghugre NR, Wright GA. Practical medical applications of quantitative MR relaxometry. J Magn Reson Imaging. 2012;36:805–824. doi: 10.1002/jmri.23718. [DOI] [PubMed] [Google Scholar]
  • 27.Alhamami M, Bayat Mokhtari R, Ganesh T, Tchouala Nofiele J, Yeger H, Margaret Cheng HL (2014) Manganese-enhanced magnetic resonance imaging for early detection and characterization of breast cancers. Mol Imaging [DOI] [PubMed]
  • 28.Aydar E, Yeo S, Djamgoz M, Palmer C. Abnormal expression, localization and interaction of canonical transient receptor potential ion channels in human breast cancer cell lines and tissues: a potential target for breast cancer diagnosis and therapy. Cancer Cell Int. 2009;9:23. doi: 10.1186/1475-2867-9-23. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Baio G, Fabbi M, Emionite L, et al. In vivo imaging of human breast cancer mouse model with high level expression of calcium sensing receptor at 3 T. Eur Radiol. 2012;22:551–558. doi: 10.1007/s00330-011-2285-1. [DOI] [PubMed] [Google Scholar]
  • 30.Braun RD, Bissig D, North R, Vistisen KS, Berkowitz BA (2012) Human tumor cell proliferation evaluated using manganese-enhanced MRI. PLoS One 7:e3057231 [DOI] [PMC free article] [PubMed]
  • 31.Braun RD, Gradianu M, Vistisen KS, Roberts RL, Berkowitz BA. Manganese-enhanced MRI of human choroidal melanoma xenografts. Invest Ophthalmol Vis Sci. 2007;48:963–967. doi: 10.1167/iovs.06-1156. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Ganesh T, Mokhtari RB, Alhamami M, Yeger H, Cheng HL. Manganese-enhanced MRI of minimally gadolinium-enhancing breast tumors. J Magn Reson Imaging. 2015;41:806–813. doi: 10.1002/jmri.24608. [DOI] [PubMed] [Google Scholar]
  • 33.Hasegawa S, Koshikawa-Yano M, Saito S, et al. Molecular imaging of mesothelioma by detection of manganese-superoxide dismutase activity using manganese-enhanced magnetic resonance imaging. Int J Cancer. 2011;128:2138–2146. doi: 10.1002/ijc.25547. [DOI] [PubMed] [Google Scholar]
  • 34.Mihai R, Stevens J, McKinney C, Ibrahim NB. Expression of the calcium receptor in human breast cancer—a potential new marker predicting the risk of bone metastases. Eur J Surg Oncol. 2006;32:511–515. doi: 10.1016/j.ejso.2006.02.009. [DOI] [PubMed] [Google Scholar]
  • 35.Nofiele JT, Czarnota GJ, Cheng HL (2014) Noninvasive manganese-enhanced magnetic resonance imaging for early detection of breast cancer metastatic potential. Mol imaging [DOI] [PubMed]
  • 36.Seshadri M, Hoy A. Manganese-enhanced MRI of salivary glands and head and neck tumors in living subjects. Magn Reson Med. 2010;64:902–906. doi: 10.1002/mrm.22452. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Suero-Abreu GA, Praveen Raju G, Aristizabal O, et al. In vivo Mn-enhanced MRI for early tumor detection and growth rate analysis in a mouse medulloblastoma model. Neoplasia. 2014;16:993–1006. doi: 10.1016/j.neo.2014.10.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Robbins D, Zhao Y. Manganese superoxide dismutase in cancer prevention. Antioxid Redox Signal. 2014;20:1628–1645. doi: 10.1089/ars.2013.5297. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Dhar SK, St Clair DK. Manganese superoxide dismutase regulation and cancer. Free Radic Biol Med. 2012;52:2209–2222. doi: 10.1016/j.freeradbiomed.2012.03.009. [DOI] [PubMed] [Google Scholar]
  • 40.Saito S, Hasegawa S, Sekita A, et al. Manganese-enhanced MRI reveals early-phase radiation-induced cell alterations in vivo. Cancer Res. 2013;73:3216–3224. doi: 10.1158/0008-5472.CAN-12-3837. [DOI] [PubMed] [Google Scholar]
  • 41.Gianolio E, Arena F, Di Gregorio E, et al. MEMRI and tumors: a method for the evaluation of the contribution of Mn(II) ions in the extracellular compartment. NMR Biomed. 2015;28:1104–1110. doi: 10.1002/nbm.3349. [DOI] [PubMed] [Google Scholar]
  • 42.Hasegawa S, Saito S, Koshikawa-Yano M, Furukawa T, Aoki I, Saga T. Tumor enhancement effect of overexpressed manganese-superoxide dismutase in manganese-enhanced MR imaging. Magn Reson Med Sci. 2011;10:155–158. doi: 10.2463/mrms.10.155. [DOI] [PubMed] [Google Scholar]
  • 43.Kuo PH, Kanal E, Abu-Alfa AK, Cowper SE. Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. Radiology. 2004;242:647–649. doi: 10.1148/radiol.2423061640. [DOI] [PubMed] [Google Scholar]
  • 44.Kanal E, Tweedle MF. Residual or retained gadolinium: practical implications for radiologists and our patients. Radiology. 2015;275:630–634. doi: 10.1148/radiol.2015150805. [DOI] [PubMed] [Google Scholar]
  • 45.Quattrocchi CC, van der Molen AJ. Gadolinium retention in the body and brain: is it time for an international joint research effort? Radiology. 2017;282:12–16. doi: 10.1148/radiol.2016161626. [DOI] [PubMed] [Google Scholar]
  • 46.Leander P, Golman K, Mansson S, Hoglund P. Orally administered manganese with and without ascorbic acid as a liver-specific contrast agent and bowel marker for magnetic resonance imaging: phase I clinical trial assessing efficacy and safety. Invest Radiol. 2010;45:559–564. doi: 10.1097/RLI.0b013e3181e960ab. [DOI] [PubMed] [Google Scholar]
  • 47.Felton C, Karmakar A, Gartia Y, Ramidi P, Biris AS, Ghosh A. Magnetic nanoparticles as contrast agents in biomedical imaging: recent advances in iron- and manganese-based magnetic nanoparticles. Drug Metab Rev. 2014;46:142–154. doi: 10.3109/03602532.2013.876429. [DOI] [PubMed] [Google Scholar]

Articles from European Radiology Experimental are provided here courtesy of Springer

RESOURCES